Deaths in trials should always be reported

BMJ. 2013 Jul 4:347:f4219. doi: 10.1136/bmj.f4219.
No abstract available

MeSH terms

  • Carbamates / adverse effects
  • Carbamates / therapeutic use
  • Clinical Trials as Topic / standards*
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Mortality*
  • Piperidines / adverse effects
  • Piperidines / therapeutic use
  • Sulfonylurea Compounds / adverse effects

Substances

  • Carbamates
  • Hypoglycemic Agents
  • Piperidines
  • Sulfonylurea Compounds
  • repaglinide